GlassScriptPhysician profile
Michael Bulloch
NPI 1700149804
$2,240.15
in general payments reported to CMS, 2019-2025
30 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $228 · 2021: $316 · 2022: $479 · 2023: $234 · 2024: $432 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.79 | 2021-2025 | Vraylar |
| Pfizer INC. | $320.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.82 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $138.95 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $136.95 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $92.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $75.83 | 2020-2021 | |
| Lilly USA, LLC | $62.58 | 2022-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $60.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $60.30 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $56.82 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $48.36 | 2020-2024 | Airsupra |
| Allergan, INC. | $47.79 | 2019-2020 | |
| Boston Scientific Corporation | $32.95 | 2022-2025 | Watchman Flx |
| Dexcom, INC. | $31.15 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $30.30 | 2021-2023 | Yupelri |
| Inspire Medical Systems, INC. | $28.99 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $25.37 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.37 | 2019 | |
| Acorda Therapeutics, INC | $19.53 | 2019 | |
| Optinose US, INC. | $19.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.56 | 2022 | |
| Lundbeck LLC | $18.37 | 2024 | Rexulti |
| Nevro Corp. | $17.29 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.74 | 2022 | |
| Amgen INC. | $16.29 | 2024 | Evenity, Prolia |
| Sanofi Pasteur INC. | $15.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.39 | 2024 | |
| Exact Sciences Corporation | $14.27 | 2025 | The Cologuard Plus Collection Kit |
| Inogen, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bulloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.